Community-acquired Pneumonia in Buskerud County in Norway
The purpose of this study is to determine the etiology of community-acquired pneumonia, to assess risk factors and to investigate potential prognostic biomarkers of serious disease and fatal outcome.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Community-acquired Pneumonia: A Prospective Observational Study to Explore Etiology, Risk Factors and Potential Predictors for re- Admittance to Hospital and All-cause Mortality|
- all cause mortality [ Time Frame: one year ] [ Designated as safety issue: No ]
- Re-admission to hospital [ Time Frame: One month ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
whole blood, serum, plasma, blood culture, airways specimens, urine
|Study Start Date:||January 2008|
|Study Completion Date:||January 2012|
|Primary Completion Date:||January 2011 (Final data collection date for primary outcome measure)|
Adults with CAP admitted to hospital
All adult patients with CAP admitted to Vestre Viken HF-Buskerud Hospital (VVHF-BH), a 400-bed community general hospital, between January 2008 og January 2011 were evaluated for inclusion in the study.
Background: This project addresses an important challenge in international medicine: Pneumonia as the leading cause of death from infection in developed countries. Purpose: (A) Determine the etiology of CAP among adult hospitalized patients- especially the occurrence of mixed infections- by systematic implementation of combined conventional and new diagnostic methods. (B) Assess risk factors of CAP, such as COPD, congestive heart failure, smoking, malignancy etc., predictive of re-admittance to hospital and mortality. (C) Examine the prognostic value of potential predictors in relation to all-cause mortality in adult patients hospitalized with CAP. Design: Prospective observational study with inclusion of 270 adult patients during a 3-year period, who all required admission for pneumonia in a community hospital setting. Clinical and biochemical data was recorded longitudinally by inclusion, at stable clinical situation and after 6 weeks, and mortality and need for re-admission within 12 months. Patients were examined systematically, using modern research methods to explore relevant microbes. At all points, blood tests were sampled for clinical-chemical analysis, DNA, RNA and immunological analyses. Application: A translational research approach with the ambitions to elucidate new pathogenic mechanisms which could lead to new diagnostic tools and treatment modalities. This will possibly lead to less drug exposure and unnecessary hospitalization both of which have positive consequences for patients and medical care costs.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01563315
|Vestre Viken Hospital Trust|
|Drammen, Buskerud, Norway, 3004|
|Study Director:||Lars Heggelund, MD, PhD||Vestre Viken Hospital Trust and Oslo University Hospital|
|Study Chair:||Einar Husebye, MD, PhD||Vestre Viken Hospital Trust|
|Principal Investigator:||Jan C Holter, MD||Vestre Viken Hospital Trust|